Case Study: BioVersys advances collaborative AMR drug discovery with CDD Vault

BioVersys unifies AMR data across 4 countries with CDD Vault

BioVersys, a Swiss biotech company combating antimicrobial resistance (AMR), faced challenges in managing its growing chemical, biological, and clinical data across multiple international teams and partners. Their manual, person-dependent processes were error-prone and hindered collaboration on critical projects targeting resistant pathogens like MRSA and tuberculosis. To support its expanding pipeline, BioVersys needed a centralized and scalable solution, leading them to implement CDD Vault from Collaborative Drug Discovery.

Using CDD Vault, BioVersys created a shared data environment that unified research and enabled real-time insight sharing. The platform provided structured data formatting, side-by-side analysis tools, and secure access, which streamlined internal workflows and enhanced collaboration with external consortia. As a result, BioVersys achieved more confident decision-making in lead optimization, supported global AMR surveillance efforts, and built a scalable foundation for collaborative drug discovery from early screening to clinical readiness.

BioVersys